Evidence map›Paper›PMID 42081272›Full record

ReviewThe Pediatric infectious disease journal2026

Infliximab in a Child With Relapsing Tuberculous Meningoencephalitis: A Case Report and Literature Review.

Chiara Barone, Martina Capitani, Beatrice Fresch, Chiara Veredice, Marco Piastra, Paolo Frassanito, Roberta Onesimo, Danilo Buonsenso

Abstract readCase ReportsReview
In one paragraph

Review in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiara BaroneFrom the Area Pediatrica, Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.
Martina CapitaniMedicine and Sugery, Università Cattolica del Sacro Cuore, Roma, Italia.
Beatrice FreschFrom the Area Pediatrica, Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.
Chiara VerediceChild Neurology and Psychiatry Unit, Department of Neuroscience, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Marco PiastraPaediatric Intensive Care Unit and Trauma Centre, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Paolo FrassanitoPediatric Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Roberta OnesimoFrom the Area Pediatrica, Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.
Danilo BuonsensoFrom the Area Pediatrica, Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.ORCID 0000-0001-8567-2639

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 5-year-old child with tuberculous meningoencephalitis developed severe drug-induced hepatitis after conventional antitubercular therapy. Consequently, standard treatment was discontinued, and second-line drugs were administered in combination with high-dose corticosteroids. However, the disease continued to progress significantly. The introduction of infliximab resulted in substantial clinical and radiologic improvement, highlighting its potential role in managing refractory cases of central nervous system tuberculosis.

Indexed as

Antitubercular AgentsInfliximabMeningoencephalitisTuberculosis, MeningealChemical and Drug Induced Liver InjuryChild, PreschoolHumansMaleRecurrenceTreatment OutcomeAntitubercular AgentsInfliximabinfliximabmeningitistuberculomastuberculosis

Identifiers

PMID42081272
PMCPMC13557465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.